Formation Bio signs deal for TYK2 drug from China's Lynk
Since Takeda paid billions for Nimbus Therapeutics' program in 2022, TYK2 has been one of immunology's hottest targets. But it's also crowded, with biotechs herding into the signs of success and...
View ArticlePsiThera gets $47.5M for oral I&I drugs after spinning out from Roivant
A biotech with plans to make an oral drug that has the same target as Humira, formerly the world's top-selling medicine, has raised $47.5 million in a Series A. The money arrived last year, but ...
View Article#SABCS25: Roche’s breast cancer pill cuts post-surgery disease recurrence...
Patients who were given Roche’s experimental breast cancer pill directly after having surgery were 30% less likely to have invasive disease recurrence than those who were given standard of care,...
View ArticleJ&J joins 'menin party' at ASH; GSK to work with Oxford BioTherapeutics
Plus, news about Sanofi, InduPro Therapeutics, Denali and Biocytogen: 📊 Johnson & Johnson's menin inhibitor data at #ASH25: Kura and Syndax weren’t the only companies to present menin ...
View ArticleIn a first, FDA approves a gene therapy from a nonprofit
The FDA on Tuesday approved a gene therapy for a rare immune disease called Wiskott-Aldrich syndrome, for which patients have little options besides a bone marrow transplant. The gene therapy will be...
View ArticleAdare Pharma shutters Philadelphia site and lays off over 100 staffers
CDMO Adare Pharma Solutions is closing a facility in Philadelphia and letting go of 137 workers, a little over a year after relocating its headquarters to Pennsylvania. The 128,000 square foot site...
View ArticleUSAntibiotics scores sped-up approval for amoxicillin
USAntibiotics on Tuesday won approval for its American-made version of extended-release amoxicillin, about two months faster than normal. It is the first product to win approval as part of FDA...
View ArticleApple Tree files for bankruptcy as it seeks funds from Russian billionaire...
VC firm Apple Tree Partners filed for voluntary Chapter 11 relief in US bankruptcy court on Wednesday, seeking to restructure and keep its portfolio afloat as it continues an effort to get its main...
View ArticleInvestors buy up stocks in biggest follow-on offering day in biotech history
A record-setting $3.2 billion in biotech follow-on stock offerings were sold over the last 24 hours, another indication of public investors’ appetite for the sector. From late Tuesday evening into...
View ArticleHouse backs Biosecure Act aimed at Chinese companies
A diluted form of the Biosecure Act appears close to becoming law, after the House on Wednesday approved a defense bill that includes the measure. Biosecure would restrict federal contracts with some...
View ArticleLilly’s triple agonist posts strongest weight loss data yet, unusual skin...
One of the most closely watched obesity assets in the clinic, Lilly’s triple-G agonist retatrutide, caused patients with obesity and knee osteoarthritis to lose an average of 23.7% of their body weight...
View ArticleEndpoints 100 survey 2025: Biotech CEOs are feeling more upbeat
Biotech hit rock bottom last spring as DOGE ran rampant and President Donald Trump beat the drum for historic tariffs. So for our second-half survey of biotech execs, largely CEOs, we dove right into...
View ArticleWeight loss biotech Prolynx gets $70M, snags Amgen's obesity commercial...
As the biopharma industry moves into the next generation of anti-obesity medications, long-acting treatments have become one of the focal points. Prolynx, a biotech 15 years in the making, wants to get...
View ArticleZealand inks deal with OTR Therapeutics as it spells out broader metabolic...
Zealand Pharma is spending at least $20 million upfront to discover and develop new targets for metabolic diseases together with Shanghai-based biotech OTR Therapeutics. The deal is part of the Danish...
View ArticleHealth tech investors are getting creative with exits
As the health tech market slowly picks back up, investors are thinking outside the box with ways to get their money back. After a roller coaster of uncertainty in the markets earlier this year, most ...
View ArticleCorbus’ obesity pill posts muted weight loss data; Disco adds another €16M in...
Plus, news about AstraZeneca, Moderna, Nanexa, Phare Bio, Basilea Pharmaceutica, Immunovant and Aukera Therapeutics: 💊 Corbus Pharmaceuticals reports obesity pill data: Nine patients with obesity given...
View ArticleAC Immune says early biomarker data are promising in Parkinson's, but...
Swiss biotech AC Immune, researching immunological treatments for neurodegenerative disorders, reported interim Parkinson’s disease data Thursday, suggesting it may slow the progression of the...
View ArticleRhythm reports Imcivree’s key weight loss data from Phase 2 Prader-Willi trial
Rhythm Pharmaceuticals unveiled initial data from a mid-stage study of its MC4R agonist in patients with a rare disease that causes excessive hunger. The biotech’s Imcivree led to BMI reductions in six...
View ArticleRezolute crashes as its only drug fails in Phase 3
Share price falls of 90% are mercifully rare in biopharma — but as Rezolute discovered Thursday, not entirely unknown. The wholesale failure of the Phase 3 trial of the company's only drug, which is...
View ArticleUmoja delays first readout for in vivo CAR-T therapy
Umoja Biopharma, one of the most well-capitalized developers of in vivo CAR-T therapy, is delaying its first clinical readout from its China-based first trial. The startup told Endpoints News that it...
View Article